Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
CNY 11.25
(2.18%)
CNY 11.25
(2.18%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 461.02 Million CNY | 10.0% |
| 2022 | 447.94 Million CNY | 28.69% |
| 2021 | 348.06 Million CNY | 34.36% |
| 2020 | 259.05 Million CNY | 38.06% |
| 2019 | 187.63 Million CNY | 142.6% |
| 2018 | 77.34 Million CNY | 107.07% |
| 2017 | 37.35 Million CNY | -32.02% |
| 2016 | 54.94 Million CNY | 9.24% |
| 2015 | 50.29 Million CNY | 129.04% |
| 2014 | 21.95 Million CNY | 3.63% |
| 2013 | 21.19 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 144.71 Million CNY | 44.19% |
| 2024 Q1 | 100.36 Million CNY | -37.47% |
| 2024 Q3 | 116.71 Million CNY | -17.09% |
| 2023 Q4 | 160.51 Million CNY | 22.58% |
| 2023 Q3 | 130.95 Million CNY | 17.16% |
| 2023 FY | 492.71 Million CNY | 10.0% |
| 2023 Q1 | 55.41 Million CNY | -65.56% |
| 2023 Q2 | 111.77 Million CNY | 101.69% |
| 2022 Q2 | 106.42 Million CNY | 83.04% |
| 2022 Q1 | 58.14 Million CNY | -63.61% |
| 2022 FY | 447.94 Million CNY | 28.69% |
| 2022 Q4 | 160.92 Million CNY | 31.42% |
| 2022 Q3 | 122.44 Million CNY | 15.05% |
| 2021 Q2 | 67.65 Million CNY | 67.83% |
| 2021 Q4 | 159.79 Million CNY | 98.97% |
| 2021 Q1 | 40.3 Million CNY | 137.99% |
| 2021 FY | 348.06 Million CNY | 34.36% |
| 2021 Q3 | 80.31 Million CNY | 18.72% |
| 2020 Q2 | 81.54 Million CNY | 397.76% |
| 2020 FY | 259.05 Million CNY | 38.06% |
| 2020 Q3 | -72.67 Million CNY | -189.13% |
| 2020 Q4 | -106.09 Million CNY | -45.98% |
| 2020 Q1 | -27.38 Million CNY | 56.9% |
| 2019 Q1 | -25.31 Million CNY | 0.0% |
| 2019 FY | 187.63 Million CNY | 142.6% |
| 2019 Q4 | -63.53 Million CNY | 0.0% |
| 2018 Q1 | 10.45 Million CNY | -7.09% |
| 2018 Q2 | 10.45 Million CNY | 0.0% |
| 2018 FY | 77.34 Million CNY | 107.07% |
| 2017 Q4 | 11.25 Million CNY | 0.0% |
| 2017 FY | 37.35 Million CNY | -32.02% |
| 2017 Q1 | 8.78 Million CNY | -50.55% |
| 2017 Q3 | 11.25 Million CNY | 28.11% |
| 2017 Q2 | 8.78 Million CNY | -0.0% |
| 2016 Q1 | 9.7 Million CNY | -29.08% |
| 2016 Q4 | 17.76 Million CNY | 0.0% |
| 2016 FY | 54.94 Million CNY | 9.24% |
| 2016 Q3 | 17.76 Million CNY | 83.17% |
| 2016 Q2 | 9.7 Million CNY | -0.0% |
| 2015 Q3 | 13.67 Million CNY | 7.65% |
| 2015 Q2 | 12.7 Million CNY | -0.0% |
| 2015 Q1 | 12.7 Million CNY | 0.0% |
| 2015 FY | 50.29 Million CNY | 129.04% |
| 2015 Q4 | 13.67 Million CNY | 0.0% |
| 2014 FY | 21.95 Million CNY | 3.63% |
| 2013 FY | 21.19 Million CNY | 0.0% |